Last reviewed · How we verify
S-1, Gemcitabine, Cisplatin
At a glance
| Generic name | S-1, Gemcitabine, Cisplatin |
|---|---|
| Also known as | S-1;TS-1, Gemcitabine;gemzer, Cisplatin;Cispulan |
| Sponsor | Kansai Hepatobiliary Oncology Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors (PHASE2)
- Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (PHASE2)
- Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma (PHASE2)
- Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |